Abstract: A hybridoma which produces monoclonal antibodies having a high affinity and selectivity for digoxin is produced by immunizing mice with digoxin, fusing the spleen cells from the treated mice with mice myeloma cells, separating hybrids from non-fused cells, selecting the hybrids which produce monoclonal antibodies directed against digoxin and isolating the hybrids.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen; alkyl of 1 to 7 carbon atoms; cycloalkyl of 3 to 7 carbon atoms; monosubstituted alkyl of 1 to 3 carbon atoms, where the substituent is pyridyl, methypyridyl, phenyl, mono-, di- or trisubstituted phenyl, where the substituents on the phenyl ring, which may be identical to or different from each other, are selected from the group consisting of one amino, one dimethylamino, one to two hydroxyls, one to three methoxys and one to three halogens; .omega.-monosubstituted alkyl of 2 to 4 carbon atoms, where the substituent is hydroxyl or di(alkyl of 1 to 3 carbon atoms)amino; phenyl; monohalo-phenyl; unsubstituted or monosubstituted straight or branched alkanoyl of 1 to 6 carbon atoms, where the substituent is phenyl, methoxyphenyl or cycloalkyl of 3 to 7 carbon atoms; or unsubstituted or monosubstituted phenylsulfonyl, where the substituent is methyl or methoxy; andR.sub.

Abstract: This invention relates to a sintering process. More particularly, this invention relates to a process for preparing a sintered form having a tungsten content which comprises the steps of:(a) sintering a porous form of pressed tungsten alloy powders having a high tungsten content in solid phase, and(b) heat treating the sintered part from step (a) in a liquid phase.

Abstract: The invention is directed to novel galenic preparation forms for providing an oral anti-diabetic agent having an improved release of active substance and processes for producing these preparation forms. The novel pharmaceutical compositions are characterized in that the onset of the activity and the duration of activity are adapted to the particular needs of diabetics with regard to proper control of the metabolism and the associated proper release of insulin. A basic or acidic excipient in a solvent is added to the anti-diabetic active substance in a quantity such that the active substance is made soluble, and then a solubilizing agent is added. Polyvinyl pyrrolidone is dissolved as carrier in this solution, but the carrier may simultaneously serve as the solubilizing adjuvant. This solution is further processed with other excipients to form corresponding preparation forms.

Abstract: There are disclosed novel imidazole derivatives of the formula. ##STR1## and derivatives of the formula ##STR2## the tautomers thereof, and non-toxic, pharmacologically acceptable addition salts thereof with inorganic or organic acids. The compounds described herein are useful in treating cardiac insufficiency.

Abstract: The invention relates to 5,6-dihydro-pyrrolo[2,1-a]isoquinolines of the formula ##STR1## wherein R, R.sup.2, R.sup.3, and R.sup.7, which may be identical or different, each represent a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms;R.sup.1 represents a cyano, hydroxycarbonyl, or alkoxycarbonyl group having from 1 to 4 carbon atoms or a primary or secondary, substituted or unsubstituted, aliphatic, cycloaliphatic, araliphatic, aromatic, or heterocyclic aminocarbonyl group;R.sup.4 and R.sup.8, which may be identical or different, each represent a hydrogen atom, a hydroxyl group, an alkoxy or alkylthio group having up to 4 carbon atoms, or an NR.sup.9 R.sup.10 group;R.sup.5 and R.sup.6, which may be identical or different, each represent a hydroxy atom or an alkoxy or alkylthio group having from 1 to 4 carbon atoms, or together represent an --O--CH.sub.2 --O--, --O--CH.sub.2 --CH.sub.2 --O--, or --O--CH.dbd.CH--O group;R.sup.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is a substituted alkoxy group, or an optionally substituted mercapto or amino group,R.sub.2 is a cyclic imino group,R.sub.3 is hydrogen, phenyl, alkyl or acyl, andn is 2 or 3,and non-toxic, pharmacologically acceptable acid addition salts thereof; the compounds as well as their salts are useful as antithrombotics.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is hydrogen, alkyl of 1 to 6 carbon atoms or phenyl(alkyl of 1 to 6 carbon atoms);R.sub.2 is hydrogen, alkyl of 1 to 4 carbon atoms or phenyl(alkyl of 1 to 6 carbon atoms);R.sub.3 is hydrogen or alkyl of 1 to 6 carbon atoms;n and m are each independently 0, 1 or 2, the sum of n and m being 1 or 2;X, Y and Z are each independently oxygen, sulfur, --NR.sub.4 --, .dbd.CR.sub.5 --, --CHR.sub.5 --, ##STR2## provided that only one of X, Y and Z is O, S ##STR3## and one or two of X, Y and Z are --NR.sub.4 --; R.sub.4 is hydrogen or alkyl of 1 to 4 carbon atoms; andR.sub.5 is hydrogen or, together with a vicinal radical R.sub.5, a phenyl ring, or when m and n are both 1, the dihydro form with its double bond in conjugation with the C-terminal carboxylic group;or a non-toxic, pharmacologically acceptable salt thereof. The compounds as well as their salts are useful as antihypertensives.

Abstract: A novel divisible delayed release pharmaceutical tablet, wherein the rate of release of active ingredient is independent of the size and nature of the total surface area, and the fragments of which have the same characteristics of release of active ingredient as the undivided tablet.